Updated from 3:40 p.m. ET to include Third Avenue Management comments and closing share prices.
NEW YORK (TheStreet) -- It took Devon Energy (DVN) about a decade to grow from a bit player into the biggest independent energy producer in the United States. Now, it may take nearly as long for the driller to prove it can dismantle that sprawling empire.
Devon's woes are similar to those of Chesapeake Energy (CHK), Occidental Petroleum (OXY), and Hess (HES) who over-expanded during the 2000's and found themselves short on cash in the years after the financial crisis. Unlike its competitors, Devon hasn't faced the pressure of an activist investor as it restructures. That speaks to the change underway at Devon and, possibly, the scale of the company's issues.
Hot Low Price Stocks To Buy Right Now: Gale Pacific Ltd (GAP)
Gale Pacific Limited is an Australia-based company engaged in marketing, sales, manufacture and distribution of screening, shading and home improvement products to global markets.The Company operates in one business segment, being the branded shading, screening and home improvement products. The Company products are sold to consumer and industrial markets including the retail and home furnishing, architectural, construction, and agribusiness markets. The Company manufactures sources and markets advanced durable knitted and woven polymer fabrics and structures made from these fabrics. The Company's retail products are marketed under the Coolaroo brand. The Company's retail product lines include items such as shade fabrics, exterior window furnishings, gazebos, shade sails and a range of pet products. The Company sells its products in Australia, the Unites States, Europe, the Middle East, New Zealand and a number of other export markets. Advisors' Opinion:- [By Dimitra DeFotis]
Some trends and percentages:
Department store Thanksgiving online sales grew by 60% vs 2012, with mobile sales growing by 44% year over year. Perhaps a boost for clothing purveyors like Gap (GAP), whose shares are up 1% in morning trading : total online sales of apparel on Thanksgiving grew by about 41% vs. 2012, with mobile sales growing by close to 62.4% year over year. Shares of�Macy’s�(M) are flat this morning, while shares of women’s clothing seller Chico�� Fas�(CHS) are down 0.4%. Mobile represented nearly 26
Top 5 Diversified Bank Stocks To Own Right Now: Roche Holding AG (RHHBY)
Roche Holding AG is a Switzerland-based pharmaceuticals and diagnostics company. The Company belongs to the Roche Group that operates through numerous subsidiaries and associated companies located around the world. The Company�� products and services cover every stage of the healthcare process, from identifying disease susceptibilities and testing for disease in at-risk populations to prevention, diagnosis, therapy and treatment monitoring. Roche operates through two divisions: Pharmaceuticals and Diagnostics. Within the Pharmaceuticals Division there are three sub-divisions: Roche Pharmaceuticals, Genentech and Chugai. The Company�� Diagnostics Division includes five sub-divisions: Applied Science, Diabetes Care, Molecular Diagnostics, Tissue Diagnosis and Professional Diagnostics. Its activities are structured into six geographical segments: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan. In March 2009, the Company completed the acquisition of Genentech, Inc. In March 2010, the Company acquired assets from BioMicro Systems for all products associated with the Roche NimbleGen microarray workflow.
During the year ended December 31, 2008, the Company Pharmaceuticals Division marketing gained approvals for its rheumatoid arthritis medicine Actemra/RoActemra in Japan, Switzerland and the European Union. In 2008, the division initiated 12 new phase III projects in, including clinical trials of the compounds pertuzumab, for breast cancer; taspoglutide, for type two diabetes, and dalcetrapib, for cardiovascular risk reduction. As of December 31, 2008, the Pharmaceuticals Division filed 11 major new marketing applications and gained 13 major regulatory approvals. At the beginning of 2009, the division�� research and development pipeline comprised 120 clinical projects, including 62 new molecular entities (NMEs) and 58 additional indications. Forty NMEs are in phase I, 16 in phase II and six in phase III or f! iled for regulatory review.
In 2008, Roche Pharmaceuticals signed a total of 57 new agreements including seven product transactions and 43 research and technology collaborations. In May 2008, Roche acquired Piramed Limited, a UK company with therapeutic research programmes targeting the PI3-kinase pathway in oncology and inflammatory disease. In June 2008, signed licensing agreement with ThromboGenics and BioInvent for their jointly developed anticancer agent TB-403 (R7334). In September, 2008, the Company acquired Mirus Bio Corporation active in the field of ribonucleic acid interference (RNAi) delivery and completed the acquisition of ARIUS Research Inc., which has a antibody platform that identifies and selects antibodies based on their functional ability to affect disease. S Research Inc. In January 2009, Roche acquired Memory Pharmaceuticals, which develops drug candidates for the treatment of debilitating central nervous system disorders such as Alzheimer�� disease and schizophrenia.
Pharmaceuticals
Within Pharmaceuticals division, the Company is engaged in the provision of drugs the areas of oncology, anemia, cardiovascular diseases, central nervous system, infectious diseases, inflammatory and autoimmune diseases, metabolic disorders, cancer, transplantation and virology. The products offered by Roche�� Pharmaceuticals division include MabThera/Rituxan, Herceptin, Avastin, Tamiflu, CellCept, NeoRecormon, Epogin, Pegasys, Tarceva, Xeloda, Bonviva, Boniva, Lucentis, Tamiflu, Xolair, Valcyte, Cymevene, Xenical, Pulmozyme, Nutropin, Neutrogin, Rocephin, Activase, TNKase and Madopar. The products offered by the Pharmaceuticals division are sold in seven geographic regions: North America; Asia-Pacific; Western Europe; Latin America; Central and Eastern Europe, Middle East and Africa (CEMAI), and Japan.
Diagnostics
Roche�� Diagnostics Division is a supplier of in vitro diagnostics (IVDs). Its products are used to test body fluids a! nd tissue! samples to obtain information for the purpose of preventing, diagnosing, treating and monitoring disease. The Company has business areas five within the diagnostics division: Professional Diagnostics, Diabetes Care, Tissue Diagnostics, Molecular Diagnostics and Applied Science. Roche�� Diagnostics division provides IVD services, including centralized laboratory testing and point-of-care diagnostics to molecular diagnostics and diabetes self management. In addition, it supplies research tools to life scientists.
Roche Professional Diagnostics supplies instrument systems, tests, software and services. It provides point-of-care testing products to support clinical decision-making close to the patient, in doctors��offices, emergency rooms and other primary and specialty care settings. Twelve Serum Work Area assays were rolled out during the year ended December 31, 2008, across Europe and in other markets. New assays included the Elecsys anti-TSH receptor antibody assay for the diagnosis of Graves��disease the Elecsys anti-CCP antibody assay, a test to aid the diagnosis of rheumatoid arthritis, and the Roche Cystatin C clinical chemistry test for early detection of impaired kidney function, among others. Roche Diabetes Care�� products portfolio covers the entire diabetes self-management spectrum, from glucose monitoring to insulin delivery, as well as monitoring systems with integrated lancets and test strips software for storing and analyzing data. Roche Tissue Diagnostics develops and manufactures medical diagnostic instruments and reagent systems that provide automation technology for use in the diagnosis and prognosis of cancer and infectious disease. In 2008 Roche Tissue Diagnostics launched ofhe Bench- Mark Ultra, a system that performs immunohistochemistry and in situ hybridisation testing simultaneously on a single continuous and random access platform. Roche Molecular Diagnostics develops and commercializes diagnostic and blood screening platforms and tests based on Roche�� ! real-time! polymerase chain reaction (PCR) technology. Applied Science business area supplies a specific reagents and test kits for use in life sciences encompassing biology, biotechnology ,medical research, as well as disease areas like cancer and virology. Applied Science�� business area product portfolio includes such sequencing systems as LightCycler 480, LightCycler 480 II, GS FLX Titanium. In addition, Applied Science offers xCELLigence cell analyzer.
Advisors' Opinion:- [By Sean Williams]
What's coming down the pipeline
Avastin: Surprise: It's Roche's (NASDAQOTH: RHHBY ) wonder drug yet again! Roche's Avastin is in the process of being tested as a treatment for recurrent endometrial cancer and demonstrated promising results in a mid-stage trial according to the Journal of Clinical Oncology. Avastin, which is an angiogenesis inhibitor (a fancy way of saying it inhibits blood vessel growth), was tested on 52 evaluable patients and delivered a progression-free survival of at least six months for 21 of them. Overall median PFS was 4.2 months, and median overall survival came in at 10.5 months. Don't be surprised if Roche decides to pursue further studies of Avastin in recurrent endometrial cancer with these results.� AEZS-108: Currently in late-stage development by Aeterna Zentaris (NASDAQ: AEZS ) , a holding in my own portfolio, AEZS-108 is an intravenous treatment composed of a synthetic peptide carrier and doxorubicin that targets Luteinizing Hormone Releasing Hormone-receptor expressing tumors. That series of scientific jargon simply means it targets cancer cells with minimal healthy cell death relative to the current standards of treatment. In mid-stage trials, AEZS-108 delivered an overall response rate of 30.8% and a clinical benefit rate of 74.4%. These figures were enough to get AEZS-108 a special protocol assessment (SPA), which should streamline its approval if these results stay consistent in late-stage studies.
As we saw with the current treatment options, the endometrial cancer pipeline isn't filled with a lot of choices, but they are at least more encouraging than the standard care treatments we've seen over the past three decades.Your best investment
With very few investable options to choose from, since many of these treatments are off patent as they're decades old, I'm going to split my decision this week between Roche and Aeterna Zentaris for obvious reasons. - [By Dan Carroll and Max Macaluso, Ph.D.]
Glaxo's staring down some tough competition. Roche (NASDAQOTH: RHHBY ) and Bristol-Myers Squibb (NYSE: BMY ) each made hundreds of millions of dollars in sales last year after both had drugs approved for melanoma in 2011. Can Glaxo rise up to carve out a lucrative niche in this space? In the following video, Fool contributor Dan Carroll and health-care analyst Max Macaluso discuss what's in store for this company's melanoma drugs.
- [By Dimitra DeFotis]
There are two cancer vaccines on the market: Provenge, a prostate-cancer treatment from Seattle-based Dendreon�(DNDN), and Yervoy, a melanoma treatment from Bristol-Myers Squibb�(BMY), according to Dow Jones Newswires. In May, Roche�Holding (RHHBY) said its experimental cancer vaccine, called MPDL3280A, shrank tumors in 21% of 140 patients participating in a trial. It is now performing tests in lung cancer patients.
Top 5 Diversified Bank Stocks To Own Right Now: Chalmers Ltd (CHR)
Chalmers Limited is an Australia-based company engaged in transport, logistic services, warehousing and container storage, repairs and sales. The Company operated in three segments: Transport, Containers and Property. Transport consists of road transport, predominantly import/export FCL containers and the interface with logistics/ warehousing/hubbing services. Containers represent the empty container park operations concerned with handling, storage, repairs, upgrades, pretrips and so on of empty containers on behalf of shipping and leasing company customers. Property represents the capital investment Chalmers has in freeholds located in Melbourne. The Company�� subsidiaries include Chalmers Industries Pty Ltd, Chalmers (Australia) Pty Ltd and Chalmers Industries (Brisbane) Pty Ltd. Advisors' Opinion:- [By Corinne Gretler]
Chr. Hansen A/S (CHR) slid 1.7 percent to 186 kroner after Credit Suisse Group AG cut the stock to neutral, the equivalent of hold, from outperform. The brokerage said that profit from its natural-color business remains under pressure. The world�� biggest maker of dairy enzymes cut its full-year sales forecast on July 3 because of lower prices for the red pigment carmine.
Top 5 Diversified Bank Stocks To Own Right Now: Bollore SA (BOL)
Bollore SA is a France-based holding company which operates in 110 countries. The Company is active in several divisions: Bollore Africa Logistics, including freight forwarding, stevedoring, shipping lines and railways; Bollore Logistics with a presence in five continents; Bollore Energie which supplies domestic fuel and petroleum products; IER which designs, manufacture and markets terminals for controlling and reading tickets; Plastic Films for condensers, capacitors and packaging; Batteries and Supercapacitors, Electric Vehicles; Autolib��which offers a network of electric car rental; Communication and Media, which launched Digital Terrestial Television (DTT); Plantations because the Company owns oil palm and rubber plantations, through the Socfin Group and Financial Assets. As of September 27, 2012, the Company acquired minority stake in Vivendi SA and sold Direct 8 and Direct Star to Canal Plus SA. In January 2014, it acquired the outstanding 51% stake of LCN. Advisors' Opinion:- [By Sofia Horta e Costa]
Rio Tinto Group climbed 2.9 percent after saying it will cost $3 billion less than projected to increase iron ore output capacity. Boliden AB (BOL) added 3.1 percent as Morgan Stanley raised its rating on the stock. Thomas Cook Group Plc (TCG) rose 13 percent after the travel operator posted a 49 percent increase in full-year earnings. British tobacco companies slipped following a report that after a U.K. minister announced the review of cigarette packaging.
No comments:
Post a Comment